VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2021 | Bintrafusp alfa in MSI-H cancers following progression on immunotherapy

Arvind Dasari • 22 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer General Bintrafusp alfa
Immuno-Oncology

Arvind Dasari, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an ongoing Phase II study evaluating bintrafusp alfa in patients with metastatic microsatellite-high (MSI-H) cancers following progression on immunotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Genomic biomarkers in metastatic colorectal cancer

More from Arvind Dasari

8:18
The use of ctDNA in patient cancer care
Arvind Dasari • 1 Feb 2022
3:15
Investigating fruquintinib in patients with refractory metastatic CRC
Arvind Dasari • 1 Feb 2022
3:41
CIRCULATE-US: investigating the use of ctDNA to detect MRD
Arvind Dasari • 1 Feb 2022
5:05
Managing patients with CRC using ctDNA
Arvind Dasari • 22 Jan 2021

Related Videos

2:29
Overcoming resistance to immunotherapy
Grant McArthur
0:49
What impact could biosimilars have?
Wojciech Jurczak
0:57
Improving patients' circadian rhythm with yoga
Karen Mustian
1:56
Can nivolimumab aid in preventing gastrointestinal cancer progression?
Ronan Joseph Kelly
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals